Nephrology

Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.

In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.

Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.

Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.

Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.

The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.

New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.

Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.

The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN .

VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.

Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.

Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.

Yale's KAT-AKI trial found personalized EHR alerts for AKI management improved clinician actions but didn't reduce progression, dialysis, or mortality rates in patients.

Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

A posthoc analysis of the DUPLEX trial suggests patients with genetic FSGS may experience a more pronounced and sustained antiproteinuric response with sparsentan.

Overall, 8 of 20 patients had complete or partial remission of their FSGS.

RIVUR analysis suggests recurrent UTIs in children with VUR may lower eGFR, even without kidney scarring, especially in those with multiple febrile infections.

The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.

Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.

This retrospective analysis examined the current management of early and late anemia in a representative sample of the kidney transplant population in Spain.